5/14
08:06 am
tbph
Theravance Biopharma, Inc. (NASDAQ: TBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Theravance Biopharma, Inc. (NASDAQ: TBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
5/13
04:11 pm
tbph
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/13
04:05 pm
tbph
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Low
Report
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
5/9
06:00 am
tbph
Theravance Biopharma to Participate in an Upcoming Investor Conference
Low
Report
Theravance Biopharma to Participate in an Upcoming Investor Conference
5/2
08:08 am
tbph
Vicinitas Therapeutics Appoints Adam Hughes as Chief Scientific Officer [Yahoo! Finance]
Medium
Report
Vicinitas Therapeutics Appoints Adam Hughes as Chief Scientific Officer [Yahoo! Finance]
4/29
06:00 am
tbph
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
Low
Report
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
4/15
09:53 am
tbph
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength? [Yahoo! Finance]
Medium
Report
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength? [Yahoo! Finance]
4/12
08:00 am
tbph
Theravance Biopharma, Inc. (NASDAQ: TBPH) is now covered by analysts at BTIG Research. They set a "buy" rating and a $21.00 price target on the stock.
Low
Report
Theravance Biopharma, Inc. (NASDAQ: TBPH) is now covered by analysts at BTIG Research. They set a "buy" rating and a $21.00 price target on the stock.
4/10
06:09 am
tbph
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 [Yahoo
Low
Report
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 [Yahoo
4/10
06:00 am
tbph
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
Low
Report
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
3/27
01:29 pm
tbph
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report? [Yahoo! Finance]
3/21
06:09 am
tbph
TOLREMO Appoints Industry Veterans Jeff Jonker and Mike Sherman to Board of Directors [Yahoo! Finance]
Low
Report
TOLREMO Appoints Industry Veterans Jeff Jonker and Mike Sherman to Board of Directors [Yahoo! Finance]
2/28
10:46 am
tbph
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Neutral
Report
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/26
04:09 pm
tbph
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
2/26
04:05 pm
tbph
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Neutral
Report
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/22
06:10 am
tbph
Theravance Biopharma to Participate in an Upcoming Investor Conference [Yahoo! Finance]
Low
Report
Theravance Biopharma to Participate in an Upcoming Investor Conference [Yahoo! Finance]
2/22
06:00 am
tbph
Theravance Biopharma to Participate in an Upcoming Investor Conference
Low
Report
Theravance Biopharma to Participate in an Upcoming Investor Conference